Objective. The optimal type of neck dissection in head and neck squamous cell carcinoma (SCC) with clinical cervical metastases has not been determined. The following study was performed to determine the rate of regional control with selective neck dissection (SND) in these patients.
N eck dissection has been an integral part of the initial treatment of advanced stage head and neck cancers. Radical neck dissection, as described by Crile, 1 is the most comprehensive operation to remove the lymphatics of the lateral neck. However, the morbidity of this operation is quite significant in terms of shoulder dysfunction 2 and venous obstruction due to removal of the internal jugular vein in bilateral cases. Head and neck surgeons initially attempted to preserve the noninvolved structures. Thus, the ''functional neck dissection,'' developed by Suárez 3 and popularized by Bocca and Pignataro, 4 became popular in the 1970s and 1980s. After patterns of lymphatic spread of mucosal head and neck cancers were described by Lindberg 5 and Shah, 6 the concept of selective neck dissection came into existence. In selective neck dissection, only the ''at-risk'' lymphatic groups are removed. This concept soon became the standard of care, when the operation was done in the context of the clinically negative neck. Many studies have shown that elective, selective neck dissection is as effective as comprehensive neck dissection in controlling the disease in the neck, with decreased morbidity. [7] [8] [9] The next step in extending this concept was to apply selective neck dissection to the clinically positive neck, when the object of the operation is to remove known metastatic disease in the neck. The initial reports were concerning due to high rates of failure in the neck, particularly for N2/3 disease. 8 More recent studies have reported excellent regional control with selective neck dissection in selected group of patients with cervical nodal metastases, especially when adjuvant radiotherapy was used. [10] [11] [12] Many unanswered questions on this topic still remain: which patients are the best candidates for less extensive operations? What factors are associated with better or worse outcome following this operation?
In the present report, we examined a group of patients with clinical cervical nodal metastases who underwent selective neck dissection. The purpose of the study was to determine the rate of regional failure, factors associated with failure in the neck, and the effect of regional failure on disease-specific survival (DSS).
Methods
The study was approved by the institutional review board of Memorial Sloan-Kettering Cancer Center (MSKCC) before data collection. All patients treated at MSKCC head and neck service are entered into a prospective database. All previously untreated patients who underwent neck dissection with diagnosis of squamous cell carcinoma (SCC) from a head and neck mucosal primary site between 2000 and 2010 were retrospectively reviewed. Patients without clinical or radiographic evidence of cervical lymph node metastases preoperatively were excluded. Patients who underwent comprehensive neck dissection and those who did not have evidence of disease on the surgical pathology specimen were also excluded. The decision to perform selective neck dissection was at the discretion of the treating surgeon.
The following data were collected on the remaining patients: demographics, primary site, stage, extent of operation, pathologic characteristics of specimen, adjuvant treatments, recurrence, DSS, and overall survival. Stage of the disease was defined using the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual. 13 Extent of surgery was based on the classification of cervical lymphatics and standard neck dissection nomenclature as defined by the American Head & Neck Society. 14 The number of positive nodes, extracapsular spread, and total number of nodes removed were recorded. Presence of positive surgical margins at the primary site, perineural invasion, and lymphovascular invasion were also recorded. Recurrence was defined as local, regional, and distant. Regional recurrence was further divided into recurrence in the field of dissection of dissected neck and appearance of new metastatic disease in the nondissected, contralateral neck. Salvage treatments (if attempted) and outcomes were documented. Regional recurrence-free survival was defined as the time interval between the date of operation and documentation of recurrence in the neck. Patients who had not developed recurrence in the neck were censored at the time of death or last follow-up visit, whichever occurred earlier, irrespective of local and/or distant recurrence.
For DSS analysis, patients who were alive and free of disease were censored at their last follow-up visit at MSKCC or at the time of death. Patients who died after their last visit at MSKCC were recorded as died of other causes if they had been free of disease within 6 months of the date of death or a specific cause of death was mentioned in the chart. Otherwise, patients were recorded as dead of disease. Regional recurrence-free survival, DSS, and overall survival were calculated by the Kaplan-Meier method. The effects of gender, age (.60 vs \60 years), primary site, tumor stage, surgical margins, perineural invasion, lymphovascular invasion, nodal stage, number of positive nodes, extracapsular spread, and adjuvant treatments were determined by bivariate analysis using a log rank test. All variables were entered into a multinominal regression analysis model. A P value of less than .05 was considered significant. All analyses were done using SPSS Version 19 (SPSS, Inc, an IBM Company, Chicago, Illinois).
Results
From 2000 to 2010, 330 patients underwent neck dissection for mucosal SCC of the head and neck. Ninety patients with elective neck dissection and 113 with comprehensive neck dissection were excluded. One hundred twenty-seven patients were identified with clinical nodal metastases who were treated by selective neck dissection. In this group, 19 had prior treatments directed toward neck (radiotherapy) or systemic therapies (chemotherapy) and were further excluded. One hundred eight patients met the inclusion criteria. Demographic details, primary site, stage, operations, and pathology are described in Table 1 . All but 1 of the patients underwent preoperative imaging in the form of computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). Eleven (10.2%) patients had evidence of bilateral disease on preoperative assessment. The majority of patients (88%) underwent adjuvant treatment.
Median follow-up time from the date of surgery was 21 months (range, 0-114 months). During the study period, 33 (30.6%) patients were identified with recurrent disease at any site. Two-year recurrence-free survival was 69.4%. The details of recurrent disease are shown in Figure 1 . Sixteen patients (14.8%) experienced regional recurrence. All regional recurrences occurred within 15 months of surgery. Of the 16 patients with regional recurrences, 3 (18.8%) had not received adjuvant treatments. Two-year regional recurrence-free survival was 92.2%. Regional recurrence occurred in the nondissected neck in 4 (3.7%) patients, dissected neck in 7 (6.5%), and both the dissected and nondissected neck in 5 (4.6%). Therefore, failure in the dissected neck occurred in 12 patients (11.1%) ( Table 2) . In this group, 8 patients had synchronous local recurrence. Disease was limited only to the neck in 3 (2.35%) and neck and distant sites in another 3 (2.35%) patients. Thus, recurrence in the dissected neck without synchronous recurrence at the primary site occurred in 6 patients (5.5%). Ten of the 12 recurrences in the dissected neck (83.3%) occurred from oral cavity tumors and 2 from larynx primary tumors. None of the oropharynx primary tumors recurred in the dissected neck. Of the 16 patients with regional recurrence, 11 (69%) underwent salvage treatments. Four (25%) patients received chemotherapy and radiation; 3 (19%) patients, chemotherapy alone; 2 (13%) patients, surgery and chemotherapy; 1 (6%) patient, surgery; and 1 (6%) patient, radiation. Three (19%) patients (1 by surgery, 1 with surgery and chemotherapy, and 1 after chemoradiation) had complete response. Four patients (25%) had partial response, and 4 (25%) patients did not respond.
At the last follow-up, 64 (59.3%) patients were disease free, 6 (5.6%) were alive with disease, 23 patients had died of disease (21.3%), and 15 (13.9%) had died of other causes. Two-year disease-specific and overall survival were 76.9% and 64.1%, respectively. Two-year DSS was 80% for stage III disease and 75.5% for stage IV disease. Patients with regional recurrence had poorer DSS (2-year survival: 24.5% vs 86.5%). Regional recurrence and DSS by the nodal stage and adjuvant treatments are detailed in Figure 2 .
Bivariate and multivariate analyses of regional recurrence in the dissected neck and DSS are detailed in Tables  3 and 4 . On bivariate analysis, bilateral neck disease was significantly associated with poorer regional recurrence-free survival. Oral cavity tumors showed a trend toward poorer regional recurrence-free survival (P = .06). Adjuvant treatment was associated with better regional recurrence-free survival in multivariate analysis. Decreased DSS was associated with oral cavity tumors, primary tumors larger than T2, positive margins of resection, and lack of adjuvant treatments on bivariate analysis. Multivariate analysis showed positive margins at the primary site, number of positive nodes (more than 2), and adjuvant treatments as significant factors in DSS.
Discussion
Traynor et al 15 in 1996 presented a group of 36 patients with clinical and pathologic disease in the neck who underwent selective neck dissection. Recurrence in the neck occurred in 1 patient after 4 years of follow-up. Byers et al 16 investigated the patterns of failure after selective neck dissection. The study does not report the overall failure rate in the pathologically positive neck, but the failure rate for N2B disease was 5.1% in the dissected field and 2.2% in the nondissected field. In node-positive patients who underwent supraomohyoid neck dissection, the regional failure rate was 13.4% (N1 and N2B). The rate of failure in N1 disease was significantly reduced by the addition of adjuvant radiotherapy (35.7% vs 5.6%). In the study by Byers et al, 16 location of primary tumor, extracapsular extension, and location of nodes in the neck were not associated with the risk of recurrence in the neck. Ambrosch et al 11 reported a series of 254 selective neck dissections in pathologically positive nodes. More than one-third of patients were pN1 (34.6%), and the remainder were pN2. Ten percent had bilateral disease (pN2c). Extracapsular extension was present in 27% of positive specimens. The regional recurrence rate in the dissected field was 8.3%. Two patients had recurrences that potentially could have been prevented by a comprehensive neck dissection. The rate of neck recurrence at 3 years was 4.9% for pN1 disease and 12.1% for pN2. Contrary to findings by Byers et al, 16 adjuvant radiation significantly reduced the rate of regional recurrence for pN2 disease but made no significant difference in pN1 disease. Extracapsular extension was not a significant factor in regional recurrence.
Andersen et al 10 reported the results of selective neck dissection in 106 clinically and pathologically positive patients. More than half were pN1 (n = 58; 54.7%), and 28 patients were pN2 (26.4%). Thirty-six patients (34%) had evidence of extracapsular extension. Regional recurrence occurred in 6 (5.7%). The 5-year neck recurrence-free survival was 92.2%. Neck recurrence was correlated with nodal stage early in the study, but by 5 years, there was no difference in the rate of recurrence. Extracapsular spread, however, was a significant factor in both neck recurrence and DSS. More recent studies show similar results. Muzaffar 17 reported 3.3% regional recurrence with selective neck dissection in 61 patients, all treated with adjuvant radiotherapy. Patel et al 12 in 2008 reported a 4% failure rate in 72 patients, comparable to the 14% failure rate in 160 patients with comprehensive neck dissection. Shepard et al 18 in 2010 reported 4.1% regional failure in 69 patients.
In the present study, we focused on a group of patients who underwent selective neck dissection with therapeutic intent. All patients had evidence of disease in the neck preoperatively and in the surgical specimen. Our study design allows us to determine the outcome of selective neck dissection in patients with low-volume neck disease. In addition, we are able to critically analyze the soundness of the surgeon's judgment in such cases. A high rate of regional recurrence is a source of concern to the effectiveness of selective neck dissection in the therapeutic setting. As evidenced by the data, these patients were carefully selected by the treating physicians. There were no strict selection criteria at the time of the study, but the general philosophy of our service is to offer selective neck dissection to patients with low-volume disease on preoperative imaging and no clinical or radiologic evidence of extranodal extension. Of 221 patients with neck disease during this time period, only 108 (49%) were treated with selective neck dissection. Almost all patients underwent preoperative imaging. Most patients had N1 disease clinically, and there was no evidence of involvement of nonlymphatic structures. No patient with N3 disease was treated in this fashion. Most primary tumors were in the oral cavity or oropharynx. The general philosophy of our service is to recommend definitive radiotherapy or chemoradiotherapy to most larynx, oropharynx, and hypopharynx tumors. Patients with advanced laryngeal cancers who are treated by surgery will undergo comprehensive neck dissection and thus are not included in this study. On the pathology report, 35% had advanced primary tumors, almost two-thirds had N2 disease, and extracapsular extension was present in more than one-third. Most patients were treated with adjuvant postoperative radiation. Considering the relatively advanced stage of disease in our group, the rate of neck failure was very low and comparable to previous studies. When local control was achieved at the primary tumor site, only 6 failures were observed in the dissected neck (5.5%). Our findings validate previous studies that show a low recurrence rate in selective neck dissection for patients with low-volume neck disease. Similar to prior studies, all neck recurrences occurred in the first 18 months after surgery. Because isolated regional recurrences were very low in our series, we performed the regression analysis of significant factors in neck recurrence and survival, including all recurrences in the dissected neck (12 events). Bivariate analysis of factors in regional recurrence identified bilateral neck disease as significant ( Figure  3) . Site of the primary tumor also showed a strong trend toward significance (Figure 4 ). In our cohort of patients, only 1 patient had a recurrence in the neck from a base-oftongue primary tumor in the contralateral undissected neck. This patient was successfully salvaged by neck dissection.
Patients with bilateral neck disease had a significantly higher rate of regional recurrence. Even when primary site was controlled, N2C patients comprised the majority of regional recurrent cases (3 of 6). Comprehensive neck dissection might be a more fitting option in this group. Even though extracapsular extension was not significant, a trend toward higher failure rate was identified (P = .1). Adjuvant treatment was the only significant factor in multivariate analysis. The limited number of events (12) , however, makes drawing any conclusions difficult. These findings are similar to prior reports. Ambrosch et al 11 did not find extracapsular extension significant, but Andersen et al 10 identified it as significant. The number of patients who did not receive adjuvant treatments is very small. However, patients who did not have adjuvant therapy showed a higher rate of regional recurrence and poorer DSS. Most patients who did not receive adjuvant treatment had N1 disease originally, and there is no difference in recurrence in this group with and without adjuvant treatments. Only 6 patients with N2 disease did not undergo adjuvant treatment. Five had significant medical comorbidities and were not deemed fit for adjuvant treatment. One patient with T1 tonsil cancer, completely excised and no adverse features, did not undergo adjuvant treatment. This patient was disease free 9 years after treatment. The rate of regional recurrence in N2B disease is almost similar to N1 disease when adjuvant treatments are used but much higher without them. Once again, the small number of patients excludes drawing any conclusions. This observation is similar to the findings by Ambrosch et al. 11 Our policy is to recommend adjuvant radiotherapy to all patients with positive nodes regardless of the nodal stage.
Analysis of DSS shows an interesting contrast between significant factors in regional recurrence and survival. Patients who experience any recurrence have poorer survival. Factors related to the primary tumor appear to be more influential in the eventual course of the disease. Location (oral cavity), extent (T stage, number of positive nodes), and adequacy of treatment (surgical margins, adjuvant treatments) all were significant predictors of DSS. These are known important prognosticating factors. Neither bilateral neck disease nor extracapsular extension was significant. It is hard to draw conclusions based on retrospective observations, but this could be due to the effective treatments for regional recurrence (salvage neck dissection, re-radiation). Of the 5 patients with isolated regional recurrence, 1 underwent salvage surgery and 2 received radiation and chemotherapy. Two were salvaged, and 1 did not respond to treatment.
The difference in regional recurrence between oral cavity and oropharynx tumors is worthy of attention. To our knowledge, none of the prior studies have identified a difference in the rate of ''regional recurrence,'' after standard treatments, related to the primary site. Nonsmokers and nondrinkers with human papillomavirus (HPV)-associated oropharyngeal cancers have better survival outcome with standard treatments, 19 but we are not aware of any study that shows lower regional recurrence after selective neck dissection for oropharyngeal tumors in comparison to oral cavity tumors. Because we do not have data on HPV status of specimens and did not design our study to identify differences in the rate of regional recurrence based on the primary site, we cannot draw any further conclusions.
Our study is limited by its design in implicating its observations to a paradigm shift in treatment strategies. The definitive answer as to which patients are the best candidates for selective neck dissection in clinical nodal metastases can be answered only in the settings of a randomized clinical trial. The history of surgical trials shows that performing such an undertaking is unlikely. Ours and other similar studies may provide the best available data to affect this difficult decision-making process.
In conclusion, we present a highly selected series of patients with cervical nodal metastases from head and neck mucosal SCC that were treated by selective neck dissection. We observed a very low rate of isolated regional failure (5.5%). Bilateral neck disease increases the risk of regional recurrence. Two-year DSS was 80% for stage III and 75.5% for stage IV disease. Oral cavity tumors, higher T stage, and positive margins increase the risk of death from the disease. Selective neck dissection with adjuvant treatment appears to be effective in controlling the disease in the neck. Careful selection of patients and use of adjuvant treatments are important factors in the success of this approach. There was a strong trend for better regional control in oropharynx primaries (P = .060). Two-year regional recurrence-free survival was 82.7% for oral cavity tumors vs 100% for oropharyngeal tumors.
